Overcoming Regorafenib Resistance in Colorectal Cancer: Synergistic Efficacy of Cilengitide in HT29 and WiDr Cells
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. Regorafenib, a multikinase inhibitor, is approved for the treatment of metastatic CRC; however, the emergence of drug resistance significantly limits its clinical efficacy. Integrins play a key role in tumor progression and therapy resistance, making them attractive therapeutic targets. Methods: Regorafenib-resistant variants of HT29 and WiDr CRC cells were established by long-term exposure to regorafenib. The cytotoxic effects of regorafenib, cilengitide (an αvβ3 and αvβ5 integrin antagonist), and their combination were assessed using MTT assays and clonogenic survival assays. Drug interactions were further evaluated using Chou-Talalay combination index analysis. Results: Resistant cells (HT29-R, WiDr-R) demonstrated markedly elevated IC50 values for regorafenib compared with their parental counterparts. Cilengitide monotherapy reduced clonogenic survival in both parental and resistant lines. Combination treatment with regorafenib and cilengitide showed synergistic inhibition of cell survival (Combination Index
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Cell Adhesion Molecules Research
Cancer Cells and Metastasis
Publication details
- Journal / source
- Medeniyet Medical Journal
- Volume
- 41
- Issue
- 1
- Pages
- 42–50
- Publication date
- 27 March 2026
- Language
- EN